FCM
TEVA icon

Farallon Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Farallon Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Sell
40,000
-314,000
-89% -$10.5M 0.01% 76
2026
Q1 		$10.7M Buy
354,000
+314,000
+785% +$10.1M 0.06% 67
2025
Q4 		$1.25M Sell
40,000
-4,957,000
-99% -$122M 0.01% 84
2025
Q3 		$101M Buy
+4,997,000
New +$87.8M 0.41% 45

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Farallon Capital Management's TEVA Position: Q2 2026 in Review

Farallon Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 89% in Q2 2026, selling an estimated $10.5M and leaving 40,000 shares worth $1.36M. The position accounts for 0.01% of the portfolio, ranked #76.

Farallon Capital Management first reported a position in TEVA in Q3 2025 and has held it in 4 quarters since. The position peaked at $101M in Q3 2025. 674 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Farallon Capital Management held 40,000 shares of Teva Pharmaceuticals worth $1.36M as of Q2 2026.
  • Farallon Capital Management sold 314,000 Teva Pharmaceuticals shares in Q2 2026, an estimated $10.5M.
  • Teva Pharmaceuticals made up 0.01% of Farallon Capital Management's portfolio in Q2 2026, its #76 holding.
  • Farallon Capital Management first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Farallon Capital Management's Teva Pharmaceuticals position peaked at $101M in Q3 2025.
  • 674 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.